The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero

Differentiation

Volumn 84, Issue 3, 2012, Pages 252-260

  Laronda, Monica M ^a   Unno, Kenji ^a   Butler, Lindsey M ^a   Kurita, Takeshi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenosis; Diethylstilbestrol; P63; TRP63; Vaginal adenocarcinoma

Indexed keywords

17ALPHA ESTRADIOL; 4,4' ISOPROPYLIDENEDIPHENOL; CLOMIFENE CITRATE; COUMESTROL; DIENESTROL; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTOR; ESTRADIOL; ESTRADIOL BENZOATE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; NAFOXIDINE; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSFORMATION RELATED PROTEIN 63; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CERVICAL ADENOSIS; CERVICAL CLEAR CELL ADENOCARCINOMA; DRUG DOSE INCREASE; EXPERIMENTAL MOUSE; FEMALE GENITAL TRACT TUMOR; GONAD DEVELOPMENT; HUMAN; INCIDENCE; INFERTILITY; MENSTRUATION DISORDER; MOLECULAR PATHOLOGY; MORNING SICKNESS; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX; UTERINE CERVIX DISEASE; VAGINA; VAGINA ADENOSIS; VAGINA EPITHELIUM; VAGINAL CLEAR CELL ADENOCARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PHOSPHOPROTEINS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TRANS-ACTIVATORS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS;

MUS;

EID: 84866043190     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2012.05.004     Document Type: Article

References (106)

1. Accetta S.G., Rivoire W.A., Monego H.I., Vettori D.V., De Oliveira Freitas D.M., Edelweiss M.I., Capp E. Vaginal adenosis in a non-diethylstilbestrol-exposed 6-year-old patient. Gynecologic and Obstetric Investigation 2001, 51:271-273.
2. Antonioli D.A., Burke L. Vaginal adenosis. Analysis of 325 biopsy specimens from 100 patients. American Journal of Clinical Pathology 1975, 64:625-638.
3. Bibbo M., Ali I., Al-Naqeeb M., Baccarini I., Climaco L.A., Gill W., Sonek M., Wied G.L. Cytologic findings in female and male offspring of DES treated mothers. Acta Cytologica 1975, 19:568-572.
4. Blaikley J.B., Dewhurst C.J., Ferreira H.P., Lewis T.L. Vaginal adenosis: clinical and pathological features with special reference to malignant change. Journal of Obstetrics and Gynaecology of the British Commonwealth 1971, 78:1115-1122.
5. Boutin E.L., Sanderson R.D., Bernfield M., Cunha G.R. Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecan. Developmental Biology 1991, 148:63-74.
6. Boyd J., Takahashi H., Waggoner S.E., Jones L.A., Hajek R.A., Wharton J.T., Liu F.S., Fujino T., Barrett J.C., McLachlan J.A. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer 1996, 77:507-513.
7. Brody J.R., Cunha G.R. Histologic, morphometric, and immunocytochemical analysis of myometrial development in rats and mice: II. Effects of DES on development. American Journal of Anatomy 1989, 186:21-42.
8. Burroughs C.D., Mills K.T., Bern H.A. Reproductive abnormalities in female mice exposed neonatally to various doses of coumestrol. Journal of Toxicology and Environmental Health 1990, 30:105-122.
9. Cebesoy F.B., Kutlar I., Aydin A. Vaginal adenosis successfully treated with simple unipolar cauterization. Journal of the National Medical Association 2007, 99:166-167.
10. Charlton A., Kirker J.A., Robertson A.K., Jones R.W. Vaginal adenosis with adenocarcinoma in situ in a woman with no recognised antecedent factors. Australian and New Zealand Journal of Obstetrics and Gynaecology 2001, 41:97-99.
11. Chattopadhyay I., Cruickshan D.J., Packer M. Non diethylstilbesterol induced vaginal adenosis--a case series and review of literature. European Journal of Gynaecological Oncology 2001, 22:260-262.
12. Couse J.F., Dixon D., Yates M., Moore A.B., Ma L., Maas R., Korach K.S. Estrogen receptor-alpha knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract. Developmental Biology 2001, 238:224-238.
13. Cunha G.R. Stromal induction and specification of morphogenesis and cytodifferentiation of the epithelia of the Müllerian ducts and urogenital sinus during development of the uterus and vagina in mice. Journal of Experimental Zoology 1976, 196:361-370.
14. Dalterio S., Bartke A., Steger R., Mayfield D. Neonatal exposure to DES in BALB/c male mice: effects on pituitary-gonadal function. Pharmacology, Biochemistry, and Behavior 1985, 22:1019-1024.
15. Dieckmann W.J., Davis M.E., Rynkiewicz L.M., Pottinger R.E. Does the administration of diethylstilbestrol during pregnancy have therapeutic value?. American Journal of Obstetrics and Gynecology 1953, 66:1062-1081.
16. Dodds E.C., Golberg L., Lawson W., Robinson R. Synthetic oestrogenic compounds related to stilbene and diphenylethane. Part I. Proceedings of the Royal Society of London, Series B: Biological Sciences 1939, 127:140-167.
17. Dodds E.C., Goldberg L., Lawson W., Robinson R. Oestrogenic activity of certain synthetic compounds. Nature 1938, 141:247-248.
18. FDA Selected item from the FDA drug bulletin-november 1971: diethylstilbestrol contraindicated in pregnancy. California Medicine 1972, 116:85-86.
19. Forsberg J.G. Estrogen, vaginal cancer, and vaginal development. American Journal of Obstetrics and Gynecology 1972, 113:83-87.
20. Forsberg J.G., Kalland T. Neonatal estrogen treatment and epithelial abnormalities in the cervicovaginal epithelium of adult mice. Cancer Research 1981, 41:721-734.
21. Gendron R.L., Paradis H., Hsieh-Li H.M., Lee D.W., Potter S.S., Markoff E. Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hoxa-11 null mice. Biology of Reproduction 1997, 56:1097-1105.
22. Gorwill R.H., Steele H.D., Sarda I.R. Heterotopic columnar epithelium and adenosis in the vagina of the mouse after neonatal treatment with clomiphene citrate. American Journal of Obstetrics and Gynecology 1982, 144:529-532.
23. Goto K., Takeuchi Y., Yakihara A., Kotsuji F. Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecologic Oncology 2005, 97:976-979.
24. Greenwald P., Barlow J.J., Nasca P.C., Burnett W.S. Vaginal cancer after maternal treatment with synthetic estrogens. New England Journal of Medicine 1971, 285:390-392.
25. Halling A. Alterations in hypothalamic and pituitary hormone levels induced by neonatal treatment of female mice with diethylstilbestrol. Reproductive Toxicology 1992, 6:335-346.
26. Halling A., Forsberg J.G. Steroid synthesis in ovarian homogenates from immature mice treated with diethylstilboestrol in neonatal life. Journal of Reproduction and Fertility 1990, 88:399-404.
27. Hart W.R., Townsend D.E., Aldrich J.O., Henderson B.E., Roy M., Benton B. Histopathologic spectrum of vaginal adenosis and related changes in stilbestrol-exposed females. Cancer 1976, 37:763-775.
28. Hashiguchi Y., Tsuda H., Inoue T., Berkowitz R.S., Mok S.C. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecologic Oncology 2006, 101:71-75.
29. Herbst A.L., Green T.H., Ulfelder H. Primary carcinoma of the vagina. An analysis of 68 cases. American Journal of Obstetrics and Gynecology 1970, 106:210-218.
30. Herbst A.L., Kurman R.J., Scully R.E., Poskanzer D.C. Clear-cell adenocarcinoma of the genital tract in young females. Registry report. New England Journal of Medicine 1972, 287:1259-1264.
31. Herbst A.L., Poskanzer D.C., Robboy S.J., Friedlander L., Scully R.E. Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed controls. New England Journal of Medicine 1975, 292:334-339.
32. Herbst A.L., Robboy S.J., Scully R.E., Poskanzer D.C. Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. American Journal of Obstetrics and Gynecology 1974, 119:713-724.
33. Herbst A.L., Scully R.E. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer 1970, 25:745-757.
34. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New England Journal of Medicine 1971, 284:878-881.
35. Hoover R.N., Hyer M., Pfeiffer R.M., Adam E., Bond B., Cheville A.L., Colton T., Hartge P., Hatch E.E., Herbst A.L., Karlan B.Y., Kaufman R., Noller K.L., Palmer J.R., Robboy S.J., Saal R.C., Strohsnitter W., Titus-Ernstoff L., Troisi R. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New England Journal of Medicine 2011, 365:1304-1314.
36. Iguchi T., Hirokawa M., Takasugi N. Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 1986, 42:1-11.
37. Iguchi T., Takasugi N. Postnatal development of uterine abnormalities in mice exposed to DES in utero. Biology of the Neonate 1987, 52:97-103.
38. Ikezuki Y., Tsutsumi O., Takai Y., Kamei Y., Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Human Reproduction 2002, 17:2839-2841.
39. Johnson L.D., Driscoll S.G., Hertig A.T., Cole P.T., Nickerson R.J. Vaginal adenosis in stillborns and neonates exposed to diethylstilbestrol and steroidal estrogens and progestins. Obstetrics and Gynecology 1979, 53:671-679.
40. Kaufman R.H., Binder G.L., Gray P.M., Adam E. Upper genital tract changes associated with exposure in utero to diethylstilbestrol. American Journal of Obstetrics and Gynecology 1977, 128:51-59.
41. Korach K.S., Sarver P., Chae K., McLachlan J.A., McKinney J.D. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted structural probes. Molecular Pharmacology 1988, 33:120-126.
42. Kurita T. Developmental origin of vaginal epithelium. Differentiation 2010, 80:99-105.
43. Kurita, T.. Normal and abnormal epithelial differentiation in the female reproductive tract. Differentiation, in press. http://dx.doi.org/10.1016/j.diff.2011.04.008.
44. Kurita T., Cooke P.S., Cunha G.R. Epithelial-stromal tissue interaction in paramesonephric (Müllerian) epithelial differentiation. Developmental Biology 2001, 240:194-211.
45. Kurita T., Cunha G.R. Roles of p63 in differentiation of Müllerian duct epithelial cells. Annals of the New York Academy of Sciences 2001, 948:9-12.
46. Kurita T., Cunha G.R., Robboy S.J., Mills A.A., Medina R.T. Differential expression of p63 isoforms in female reproductive organs. Mechanisms of Development 2005, 122:1043-1055.
47. Kurita T., Mills A.A., Cunha G.R. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. Development 2004, 131:1639-1649.
48. Kurman R.J., Scully R.E. The incidence and histogenesis of vaginal adenosis. An autopsy study. Human Pathology 1974, 5:265-276.
49. Labarthe D., Adam E., Noller K.L., O'Brien P.C., Robboy S.J., Tilley B.C., Townsend D., Barnes A.B., Kaufman R.H., Decker D.G., Fish C.R., Herbst A.L., Gundersen J., Kurland L.T. Design and preliminary observations of National Cooperative Diethylstilbestrol Adenosis (DESAD) project. Obstetrics and Gynecology 1978, 51:453-458.
50. Legler J., Brouwer A. Are brominated flame retardants endocrine disruptors?. Environment International 2003, 29:879-885.
51. Liebrich C., Brummer O., Von Wasielewski R., Wegener G., Meijer C., Iftner T., Petry K.U. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. European Journal of Gynaecological Oncology 2009, 30:45-48.
52. Lopez J., Ogren L., Talamantes F. Effects of neonatal treatment with diethylstilbestrol and 17 alpha-hydroxyprogesterone caproate on in vitro pituitary prolactin secretion. Life Sciences 1984, 34:2303-2311.
53. Lopez J., Ogren L., Talamantes F. Neonatal diethylstilbestrol treatment: response of prolactin to dopamine or estradiol in adult mice. Endocrinology 1986, 119:1020-1027.
54. Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis. Trends in Endocrinology And Metabolism 2009, 20:357-363.
55. Ma L., Benson G.V., Lim H., Dey S.K., Maas R.L. Abdominal B (AbdB) Hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in Müllerian duct by the synthetic estrogen diethylstilbestrol (DES). Developmental Biology 1998, 197:141-154.
56. Meyers R. D.E.S., The Bitter Pill 1983, Seaview/Putnam, New York.
57. Miller C., Sassoon D.A. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 1998, 125:3201-3211.
58. Minaguchi T., Yoshikawa H., Nakagawa S., Yasugi T., Yano T., Iwase H., Mizutani K., Shiromizu K., Ohmi K., Watanabe Y., Noda K., Nishiu M., Nakamura Y., Taketani Y. Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix. Cancer Letters 2004, 210:57-62.
59. Murashima A., Miyagawa S., Ogino Y., Nishida-Fukuda H., Araki K., Matsumoto T., Kaneko T., Yoshinaga K., Yamamura K., Kurita T., Kato S., Moon A.M., Yamada G. Essential roles of androgen signaling in wolffian duct stabilization and epididymal cell differentiation. Endocrinology 2011, 152:1640-1651.
60. Nakajima T., Iguchi T., Sato T. Involvement of activin signaling in abnormalities of mouse vagina exposed neonatally to diethylstilbestrol. Cell and Tissue Research 2011.
61. Naucler P., Mabota da Costa F., da Costa J.L., Ljungberg O., Bugalho A., Dillner J. Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: case-control study. Journal of General Virology 2011.
62. Newbold R.R., Jefferson W.N., Padilla-Banks E. Prenatal exposure to bisphenol a at environmentally relevant doses adversely affects the murine female reproductive tract later in life. Environmental Health Perspectives 2009, 117:879-885.
63. Newbold R.R., McLachlan J.A. Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. Cancer Research 1982, 42:2003-2011.
64. Ng A.B., Reagan J.W., Hawliczek S., Wentz W.B. Cellular detection of vaginal adenosis. Obstetrics and Gynecology 1975, 46:323-328.
65. Noller K.L., Decker D.G., Lanier A.P., Kurland L.T. Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens. Mayo Clinic Proceedings 1972, 47:629-630.
66. O'Brien P.C., Noller K.L., Robboy S.J., Barnes A.B., Kaufman R.H., Tilley B.C., Townsend D.E. Vaginal epithelial changes in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project. Obstetrics and Gynecology 1979, 53:300-308.
67. 2 laser vaporization and 5-fluorouracil therapy. International Journal of Gynecological Pathology 2010, 29:193-196.
68. Padmanabhan V., Siefert K., Ransom S., Johnson T., Pinkerton J., Anderson L., Tao L., Kannan K. Maternal bisphenol-A levels at delivery: a looming problem?. Journal of Perinatology: Official Journal of the California Perinatal Association 2008, 28:258-263.
69. Palmer J.R., Anderson D., Helmrich S.P., Herbst A.L. Risk factors for diethylstilbestrol-associated clear cell adenocarcinoma. Obstetrics and Gynecology 2000, 95:814-820.
70. Palmlund I., Apfel R., Buitendijk S., Cabau A., Forsberg J.G. Effects of diethylstilbestrol (DES) medication during pregnancy: report from a symposium at the 10th international congress of ISPOG. Journal of Psychosomatic Obstetrics and Gynaecology 1993, 14:71-89.
71. Palmlund I., Apfel R., Buitendijk S., Cabau A., Forsberg J.G. Effects of diethylstilbestrol (DES) medication during pregnancy: report from a symposium at the 10th international congress of ISPOG. Journal of Psychosomatic Obstetrics and Gynaecology 1993, 14:71-89.
72. Pirog E.C., Kleter B., Olgac S., Bobkiewicz P., Lindeman J., Quint W.G., Richart R.M., Isacson C. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. American Journal of Pathology 2000, 157:1055-1062.
73. Plapinger L., Bern H.A. Adenosis-like lesions and other cervicovaginal abnormalities in mice treated perinatally with estrogen. Journal of the National Cancer Institute 1979, 63:507-518.
74. Plaut A., Dreyfuss M.L. Adenosis of vagina and its relations to primary adenocarcinoma of vagina. Surgery, Gynecology and Obstetrics 1940, 71:756-765.
75. Robboy S.J., Friedlander L.M., Welch W.R., Keh P.C., Taft P.D., Barnes A.B., Scully R.E., Herbst A.L. Cytology of 575 young women with prenatal exposure to diethylstilbestrol. Obstetrics and Gynecology 1976, 48:511-515.
76. Robboy S.J., Hill E.C., Sandberg E.C., Czernobilsky B. Vaginal adenosis in women born prior to the diethylstilbestrol era. Human Pathology 1986, 17:488-492.
77. Robboy S.J., Young R.H., Welch W.R., Truslow G.Y., Prat J., Herbst A.L., Scully R.E. Atypical vaginal adenosis and cervical ectropion. Association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring. Cancer 1984, 54:869-875.
78. Roy J.R., Chakraborty S., Chakraborty T.R. Estrogen-like endocrine disrupting chemicals affecting puberty in humans--a review. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2009, 15:RA137-RA145.
79. Ruffolo E.H., Foxworthy D., Fletcher J.C. Vaginal adenocarcinoma arising in vaginal adenosis. American Journal of Obstetrics and Gynecology 1971, 111:167-172.
80. Sandberg E.C. The incidence and distribution of occult vaginal adenosis. Transactions of the Pacific Coast Obstetrical and Gynecological Society 1967, 35:36-48.
81. Sandberg E.C., Danielson R.W., Cauwet R.W., Bonar B.E. Adenosis vaginae. American Journal of Obstetrics and Gynecology 1965, 93:209-222.
82. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Research 2000, 60:7052-7056.
83. Schonfelder G., Wittfoht W., Hopp H., Talsness C.E., Paul M., Chahoud I. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environmental Health Perspectives 2002, 110:A703-A707.
84. Schroder A.L., Pelch K.E., Nagel S.C. Estrogen modulates expression of putative housekeeping genes in the mouse uterus. Endocrine 2009, 35:211-219.
85. Seaman B. The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth 2003, Hyperion.
86. Sherman A.I., Goldrath M., Berlin A., Vakhariya V., Banooni F., Michaels W., Goodman P., Brown S. Cervical-vaginal adenosis after in utero exposure to synthetic estrogens. Obstetrics and Gynecology 1974, 44:531-545.
87. Smith G.V., Smith O.W. Prophylactic hormone therapy; relation to complications of pregnancy. Obstetrics and Gynecology 1954, 4:129-141.
88. Smith O.W. Diethylstilbestrol in the prevention and treatment of complications of pregnancy. American Journal of Obstetrics and Gynecology 1948, 56:821-834.
89. Smith O.W., Smith G.V., Hurwitz D. Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents. American Journal of Obstetrics and Gynecology 1946, 51:411-415.
90. Smith O.W., Smith G.V.S., Schiller S. Estrogen and progestin metabolism in pregnancy. I. Spontaneous and induced labor. Journal of Clinical Endocrinology 1941, 1:461-469.
91. Sonnenschein C., Soto A.M. An updated review of environmental estrogen and androgen mimics and antagonists. Journal of Steroid Biochemistry and Molecular Biology 1998, 65:143-150.
92. Soto A.M., Chung K.L., Sonnenschein C. The pesticides endosulfan, toxaphene, and dieldrin have estrogenic effects on human estrogen-sensitive cells. Environmental Health Perspectives 1994, 102:380-383.
93. Stafl A., Mattingly R.F., Foley D.V., Fetherston W.C. Clinical diagnosis of vaginal adenosis. Obstetrics and Gynecology 1974, 43:118-128.
94. Stewart J., Bevans-Wilkins K., Ye C., Kurtycz D.F. Clear-cell endocervical adenocarcinoma in a 19-year-old woman. Diagnostic Cytopathology 2006, 34:839-842.
95. Taguchi O., Nishizuka Y. Reproductive tract abnormalities in female mice treated neonatally with tamoxifen. American Journal of Obstetrics and Gynecology 1985, 151:675-678.
96. Troisi R., Hatch E.E., Titus-Ernstoff L., Hyer M., Palmer J.R., Robboy S.J., Strohsnitter W.C., Kaufman R., Herbst A.L., Hoover R.N. Cancer risk in women prenatally exposed to diethylstilbestrol. International Journal of Cancerr 2007, 121:356-360.
97. Vandenberg L.N., Chahoud I., Heindel J.J., Padmanabhan V., Paumgartten F.J., Schoenfelder G. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environmental Health Perspectives 2010, 118:1055-1070.
98. Vandenberg L.N., Maffini M.V., Sonnenschein C., Rubin B.S., Soto A.M. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocrine Reviews 2009, 30:75-95.
99. Vassalli A., Matzuk M.M., Gardner H.A., Lee K.F., Jaenisch R. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes and Development 1994, 8:414-427.
100. Volkel W., Colnot T., Csanady G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chemical Research in Toxicology 2002, 15:1281-1287.
101. Waggoner S.E., Anderson S.M., Luce M.C., Takahashi H., Boyd J. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. Gynecologic Oncology 1996, 60:339-344.
102. Waggoner S.E., Anderson S.M., Van Eyck S., Fuller J., Luce M.C., Herbst A.L. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix. Obstetrics and Gynecology 1994, 84:404-408.
103. Waggoner S.E., Baunoch D.A., Anderson S.A., Leigh F., Zagaja V.G. Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53. Annals of Surgical Oncology 1998, 5:544-547.
104. White R., Jobling S., Hoare S.A., Sumpter J.P., Parker M.G. Environmentally persistent alkylphenolic compounds are estrogenic. Endocrinology 1994, 135:175-182.
105. Yamada H., Furuta I., Kato E.H., Kataoka S., Usuki Y., Kobashi G., Sata F., Kishi R., Fujimoto S. Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reproductive Toxicology 2002, 16:735-739.
106. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molecular Cell 1998, 2:305-316.